<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Characteristics of the hepatitis B virus and pathogenesis of infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Characteristics of the hepatitis B virus and pathogenesis of infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Characteristics of the hepatitis B virus and pathogenesis of infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna SF Lok, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rafael Esteban, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hepatitis B virus (HBV) infection is a global public health problem. The spectrum of clinical manifestations of HBV infection varies in both acute and chronic disease. During the acute phase, manifestations range from subclinical hepatitis to anicteric hepatitis, icteric hepatitis, and fulminant hepatitis; during the chronic phase, manifestations range from an asymptomatic carrier state to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. The clinical outcome of HBV infection depends upon the age at infection, the level of HBV replication, and the immune status of the host. (See  <a class="medical medical_review" href="/z/d/html/3627.html" rel="external">"Hepatitis B virus: Clinical manifestations and natural history"</a>.)</p><p>This topic review will discuss the characteristics of the hepatitis B virus and the pathogenesis of HBV-related liver disease. The immune response to HBV contributes to the hepatic injury, helps control the infection, and provides the means for establishing the serologic diagnosis of HBV infection. (See  <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">"Hepatitis B virus: Screening and diagnosis in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CHARACTERISTICS OF THE VIRUS</span><span class="headingEndMark"> — </span>Hepatitis B virus belongs to the family of hepadnaviruses, which include duck hepatitis virus, woodchuck hepatitis virus, and ground squirrel hepatitis virus. The complete virion or Dane particle is 42 nm in diameter. It consists of:</p><p class="bulletIndent1"><span class="glyph">●</span>An envelope composed of viral-encoded proteins and host-derived lipid components</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A core particle made up of the nucleocapsid protein, the viral genome, and the polymerase protein</p><p></p><p>HBV also produces 22 nm subviral particles in the form of filaments and spheres that are composed of envelope proteins only. These subviral particles do not contain the HBV genome and are therefore noninfectious [<a href="#rid1">1</a>].</p><p>The genome of HBV is a relaxed circular, partially double stranded DNA of approximately 3200 base pairs in length [<a href="#rid1">1</a>]. There are four partially overlapping open reading frames (ORFs) encoding the envelope (pre-S/S), core (precore/core), polymerase, and X proteins [<a href="#rid1">1</a>].</p><p>The pre-S/S ORF consists of three in-phase start codons and a common stop codon that divides the gene into pre-S1, pre-S2, and S regions encoding the large (L), middle (M), and small (S) envelope proteins, respectively  (<a class="graphic graphic_figure graphicRef74116" href="/z/d/graphic/74116.html" rel="external">figure 1</a>). The M and S envelope proteins are found in all forms of viral and subviral particles while the L envelope proteins are predominantly found in complete virions.</p><p>The precore/core ORF consists of two in-phase start codons  (<a class="graphic graphic_figure graphicRef61295" href="/z/d/graphic/61295.html" rel="external">figure 2</a>). Translation from the precore start codon produces a precore polypeptide which is post-translationally modified into a soluble protein, the hepatitis B e antigen (HBeAg). Translation from the second start codon produces the core protein (HBcAg).</p><p>The polymerase ORF overlaps with the core, envelope, and X ORFs. The polymerase protein consists of a protein primer, a spacer, a reverse transcriptase/DNA polymerase, and an RNAase H domain.</p><p>The X protein is a potent transcriptional transactivator of many promoters including HBV and cellular oncogenes. The HBx protein has been implicated in hepatocarcinogenesis. Studies also suggest that HBx plays a role in modulating transcriptional activity of covalently closed circular (ccc) DNA, and may be a target for antiviral therapy [<a href="#rid2">2</a>].</p><p>Two major transcripts (3.5 and 2.1 kb) are made [<a href="#rid1">1</a>]. The 3.5 kb RNA has heterogeneous 5'-ends:</p><p class="bulletIndent1"><span class="glyph">●</span>The precore mRNA is slightly longer and is initiated upstream of the precore start codon. It is translated into the precore polypeptide, which is then processed at both the N and C terminal ends to a smaller protein, the HBeAg  (<a class="graphic graphic_figure graphicRef61295" href="/z/d/graphic/61295.html" rel="external">figure 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pregenomic RNA is initiated within the precore region. It serves as a replicative intermediate and is reverse transcribed into HBV DNA  (<a class="graphic graphic_figure graphicRef61295" href="/z/d/graphic/61295.html" rel="external">figure 2</a>). In addition, it functions as a messenger RNA for translation into the nucleocapsid and polymerase proteins.</p><p></p><p>The 2.1 kb RNA is initiated within the pre-S1 region and is translated into middle and small S proteins  (<a class="graphic graphic_figure graphicRef74116" href="/z/d/graphic/74116.html" rel="external">figure 1</a>). There are also at least two minor transcripts: the 2.4 kb RNA, which is translated into the large S protein  (<a class="graphic graphic_figure graphicRef74116" href="/z/d/graphic/74116.html" rel="external">figure 1</a>), and a smaller RNA, which is translated into the X protein.</p><p class="headingAnchor" id="H3"><span class="h2">Genotypes</span><span class="headingEndMark"> — </span>HBV has been classified into 10 genotypes (A to J) based upon an intergroup divergence of 8 percent or more in the complete nucleotide sequence. HBV genotypes have been associated with a risk of hepatocellular carcinoma (HCC) development and a response to interferon therapy. (See  <a class="medical medical_review" href="/z/d/html/3644.html" rel="external">"Clinical significance of hepatitis B virus genotypes"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Replication cycle</span><span class="headingEndMark"> — </span>The replication cycle of HBV begins with attachment of the virion to the hepatocyte membrane  (<a class="graphic graphic_figure graphicRef59125" href="/z/d/graphic/59125.html" rel="external">figure 3</a>) [<a href="#rid1">1</a>]. The receptor for HBV (and hepatitis D virus) has been identified as a bile salt transporter, sodium taurocholate cotransporting polypeptide (NTCP), which binds to the pre-S1 region of the HBV envelope [<a href="#rid3">3</a>]. The virion is uncoated in the hepatocyte cytoplasm and the viral genome enters the hepatocyte nucleus. </p><p>Inside the hepatocyte nucleus, synthesis of the plus strand HBV DNA is completed and the viral genome is converted into a ccc DNA.</p><p>The HBV genome replicates by reverse transcription via an RNA intermediate, the pregenomic RNA. The pregenomic RNA, nucleocapsid, and polymerase proteins are encapsidated in the virus core particle inside which reverse transcription takes place. The pregenomic RNA is the only RNA transcript which is encapsidated. Encapsidation is regulated by the pregenome encapsidation sequence (e) which is located in the precore and proximal core region.</p><p>A new minus strand HBV DNA is produced followed by the synthesis of a new plus strand HBV DNA. Nucleocapsids with the partially double stranded HBV DNA can re-enter the hepatocyte nucleus to produce more ccc DNA or be secreted as complete virions after coating with envelope proteins. The ccc DNA appears to have a long half-life and is not inhibited by approved nucleos(t)ide analogue therapies, accounting for the difficulty in achieving virus clearance during treatment of chronic hepatitis B; however, more recent studies suggest that the half-life of ccc DNA might be weeks or months and not years, raising hopes that new therapies may be able to eliminate ccc DNA [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H5"><span class="h1">PATHOGENESIS OF INFECTION</span><span class="headingEndMark"> — </span>The pathogenesis of HBV-related liver disease is largely due to immune-mediated mechanisms. In some circumstances, HBV can also cause direct cytotoxic liver injury.</p><p class="headingAnchor" id="H6"><span class="h2">Immune-mediated liver injury</span><span class="headingEndMark"> — </span>Both innate and adaptive immune responses contribute to immune control of HBV infection, although the T cell response is a double-edge sword playing a role in both immune control as well as liver injury [<a href="#rid2">2,5-8</a>]. HBV-related liver disease is generally thought to be related to cytotoxic T cell-mediated lysis of infected hepatocytes. However, the noncytolytic T cell immune response is also important. The following observations are consistent with this hypothesis:</p><p class="bulletIndent1"><span class="glyph">●</span>Events associated with immune clearance, such as spontaneous or interferon-induced, the hepatitis B e antigen (HBeAg) seroconversion, are often accompanied by exacerbations of liver disease as evidenced by an elevated serum ALT [<a href="#rid9">9,10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with chronic hepatitis B who clear HBeAg have more vigorous cytotoxic T lymphocyte responses to HBV antigens than those who remain HBeAg positive [<a href="#rid11">11</a>]. However, in HBeAg-positive patients the T cell response to HBV among those in the immune tolerance phase is not necessarily weaker than the T cell response among those in the immune active phase. Thus, the difference between these two phases is mainly in the inflammatory response and not the T cell response [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/3627.html" rel="external">"Hepatitis B virus: Clinical manifestations and natural history", section on 'Phases of chronic HBV infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fulminant hepatitis B is believed to be due to massive immune-mediated lysis of infected hepatocytes. This explains why many patients with fulminant hepatitis B have no evidence of HBV replication at presentation.</p><p></p><p>In addition to promoting hepatic injury, both the T cell and antibody responses to HBV help to control the infection (see  <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">"Hepatitis B virus: Screening and diagnosis in adults"</a>). In one study, for example, HBV-specific cytotoxic T cells from patients studied up to 23 years after clinical and serologic recovery expressed activation markers indicating recent contact with HBV antigens [<a href="#rid13">13</a>]. This observation suggests that complete eradication of HBV rarely occurs after recovery from acute hepatitis and that traces of virus can maintain the T and B cell responses for decades following clinical recovery, which in turn keep the virus under control and maintain high levels of hepatitis B surface antibody (anti-HBs) [<a href="#rid13">13,14</a>].</p><p>In a study of five patients who were identified during the incubation phase of acute HBV infection, NK cell activation was detected first followed by HBV-specific T cell response [<a href="#rid15">15</a>]. The presence of HBV-specific CD8+ and CD4+ cells during the incubation phase suggests that these cells play an important role in the control of infection and in the initiation of events that lead to liver damage. Maximal reduction in HBV-DNA levels occurred prior to peak increase in serum ALT levels, suggesting that viral control is mediated through noncytolytic as well as cytolytic mechanisms.</p><p class="headingAnchor" id="H7"><span class="h2">Direct cytotoxic liver injury</span><span class="headingEndMark"> — </span>HBV is generally not a cytopathic virus. In most patients with chronic hepatitis B, for example, there is no direct correlation between viral load and the severity of liver disease. This is particularly true during the early phase of perinatally acquired HBV infection in which there is high serum HBV DNA but normal serum ALT concentrations [<a href="#rid16">16</a>]. Nevertheless, direct cytopathic liver injury can occur when the viral load is very high as in fibrosing cholestatic hepatitis, an unusual form of liver disease seen in some patients with recurrent hepatitis B following liver transplantation [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/4584.html" rel="external">"Liver transplantation in adults: Preventing hepatitis B virus infection in liver transplant recipients"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Role of viral variants</span><span class="headingEndMark"> — </span>Mutations in all regions of HBV have been found in patients with chronic HBV infection. Some of these mutations, such as the precore stop codon mutation, have been incriminated in causing more severe liver disease  (<a class="graphic graphic_figure graphicRef61295" href="/z/d/graphic/61295.html" rel="external">figure 2</a>) [<a href="#rid18">18-20</a>]. However, these variants have also been found in asymptomatic carriers [<a href="#rid21">21</a>], suggesting that the mutations alone are not necessarily pathogenic. Nevertheless, HBV mutations can potentially modulate the severity of liver disease by altering the level of HBV replication or the expression of immunogenic epitopes. Some variants, for example, do not make HBeAg. Nevertheless, the virus can continue to replicate (as determined by the presence of HBV DNA in serum and elevated serum ALT) [<a href="#rid22">22,23</a>] and, in the case of four surgeons, transmit the infection to others [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/3639.html" rel="external">"Clinical significance and molecular characteristics of common hepatitis B virus variants"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Development of chronic infection</span><span class="headingEndMark"> — </span>Patients who progress to chronic HBV infection have weak and limited immune response to HBV epitopes [<a href="#rid11">11,25-28</a>]. Some studies also found relatively increased activation of the host's immunosuppressive mechanisms [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H25974980"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The genome of hepatitis B virus (HBV) is a relaxed circular, partially double stranded DNA of approximately 3200 base pairs in length, and the virion is 42 nm in diameter. HBV belongs to the family of hepadnaviruses, which include the duck hepatitis virus, woodchuck hepatitis virus, and ground squirrel hepatitis virus. (See <a class="local">'Characteristics of the virus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HBV has been classified into 10 genotypes (A to J) based upon an intergroup divergence of 8 percent or more in the complete nucleotide sequence. HBV genotypes may influence hepatocellular carcinoma risk and response to interferon therapy. (See <a class="local">'Genotypes'</a> above and  <a class="medical medical_review" href="/z/d/html/3644.html" rel="external">"Clinical significance of hepatitis B virus genotypes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pathogenesis of HBV-related liver disease is largely due to immune-mediated mechanisms. In some circumstances, HBV can cause direct cytotoxic liver injury. (See <a class="local">'Pathogenesis of infection'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Scaglioni PP, Melegari M, Wands JR. Recent advances in the molecular biology of hepatitis B virus. Baillieres Clin Gastroenterol 1996; 10:207.</a></li><li><a class="nounderline abstract_t">Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol 2016; 64:S117.</a></li><li><a class="nounderline abstract_t">Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1:e00049.</a></li><li><a class="nounderline abstract_t">Huang Q, Zhou B, Cai D, et al. Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients. Hepatology 2021; 73:41.</a></li><li><a class="nounderline abstract_t">Ferrari C. HBV and the immune response. Liver Int 2015; 35 Suppl 1:121.</a></li><li><a class="nounderline abstract_t">Ma Z, Zhang E, Yang D, Lu M. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol 2015; 12:273.</a></li><li><a class="nounderline abstract_t">Zhang E, Lu M. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol 2015; 204:11.</a></li><li><a class="nounderline abstract_t">Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol 2016; 64:S71.</a></li><li><a class="nounderline abstract_t">Liaw YF, Pao CC, Chu CM, et al. Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis. Hepatology 1987; 7:1.</a></li><li><a class="nounderline abstract_t">Perrillo RP. The management of chronic hepatitis B. Am J Med 1994; 96:34S.</a></li><li><a class="nounderline abstract_t">Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996; 97:1655.</a></li><li><a class="nounderline abstract_t">Bertoletti A, Hong M. Age-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative Interpretation. Front Immunol 2014; 5:441.</a></li><li><a class="nounderline abstract_t">Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2:1104.</a></li><li><a class="nounderline abstract_t">Bernuau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986; 6:648.</a></li><li><a class="nounderline abstract_t">Webster GJ, Reignat S, Maini MK, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000; 32:1117.</a></li><li><a class="nounderline abstract_t">Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988; 8:1130.</a></li><li><a class="nounderline abstract_t">Lau JY, Bain VG, Davies SE, et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992; 102:956.</a></li><li><a class="nounderline abstract_t">Carman WF, Trautwein C, van Deursen FJ, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24:489.</a></li><li><a class="nounderline abstract_t">Sato S, Suzuki K, Akahane Y, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122:241.</a></li><li><a class="nounderline abstract_t">Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996; 98:2268.</a></li><li><a class="nounderline abstract_t">Akarca US, Greene S, Lok AS. Detection of precore hepatitis B virus mutants in asymptomatic HBsAg-positive family members. Hepatology 1994; 19:1366.</a></li><li><a class="nounderline abstract_t">Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2:588.</a></li><li><a class="nounderline abstract_t">Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91:4077.</a></li><li><a class="nounderline abstract_t">Incident Investigation Teams and Others. Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. N Engl J Med 1997; 336:178.</a></li><li><a class="nounderline abstract_t">Bertoletti A, Naoumov NV. Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol 2003; 39:115.</a></li><li><a class="nounderline abstract_t">Rehermann B, Chang KM, McHutchinson J, et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996; 70:7092.</a></li><li><a class="nounderline abstract_t">Penna A, Artini M, Cavalli A, et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98:1185.</a></li><li><a class="nounderline abstract_t">Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 93:230.</a></li><li><a class="nounderline abstract_t">Stoop JN, van der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41:771.</a></li></ol></div><div id="topicVersionRevision">Topic 3631 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8864030" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recent advances in the molecular biology of hepatitis B virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27084032" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23150796" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32189364" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25529097" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : HBV and the immune response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25418467" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25550115" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27084039" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Adaptive immunity in HBV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2433201" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8109587" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The management of chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8601631" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25295036" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Age-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative Interpretation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8837608" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3732998" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Multivariate analysis of prognostic factors in fulminant hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11050064" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3417235" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1537531" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8781312" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7825758" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8941643" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8188166" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Detection of precore hepatitis B virus mutants in asymptomatic HBsAg-positive family members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2570285" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8171038" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8992352" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12821053" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Translation of immunological knowledge into better treatments of chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8794355" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8787682" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-lasting memory T cell responses following self-limited acute hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8282792" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hepatitis B virus persistence after recovery from acute viral hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15791617" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
